Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations

Detalhes bibliográficos
Autor(a) principal: Viviane de Cássia Kanufre
Data de Publicação: 2021
Outros Autores: Manuela Ferreira Almeida, Catarina Sousa Barbosa, Carla Carmona, Anabela Bandeira, Esmeralda Martins, Sara Rocha, Arlindo Guimas, Rosa Ribeiro, Anita MacDonald, Alex Pinto, Júlio César Rocha
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFMG
Texto Completo: https://doi.org/10.3390/nu13093118
http://hdl.handle.net/1843/52415
https://orcid.org/0000-0002-1683-1314
https://orcid.org/0000-0001-7401-4016
https://orcid.org/0000-0002-9247-9391
https://orcid.org/0000-0002-8727-3743
https://orcid.org/0000-0002-4977-8345
Resumo: Blood phenylalanine (Phe) is used as the primary marker to evaluate metabolic control. Our study aimed to describe the metabolic control of patients with phenylketonuria (PKU) comparing three different treatment recommendations (European guidelines/US guidelines/Portuguese consensus). This was a retrospective, observational, single centre study in patients with PKU collecting data on blood Phe levels from 2017. Nutritional intake data and sapropterin (BH4) prescription were collected at the last appointment of 2017. The final sample studied included 87 patients (48% females) [13 hyperphenylalaninemia; 47 mild PKU; 27 classical PKU] with a median age of 18 y (range: 1–36 y). The median number of blood Phe measurements for patients was 21 (range: 6–89). In patients aged < 12 y, the median blood Phe level was 300 µmol/L (range 168–480) and 474 µmol/L (range 156–1194) for patients ≥ 12 y. Overall, a median of 83% of blood Phe levels were within the European PKU guidelines target range. In patients aged ≥ 12 years, there was a higher median % of blood Phe levels within the European PKU guidelines target range (≥12 y: 84% vs. <12 y: 56%). In children < 12 y with classical PKU (n = 2), only 34% of blood Phe levels were within target range for all 3 guidelines and 49% with mild PKU (n = 11). Girls had better control than boys (89% vs. 66% median Phe levels within European Guidelines). Although it is clear that 50% or more patients were unable to achieve acceptable metabolic control on current treatment options, a globally agreed upper Phe target associated with optimal outcomes for age groups is necessary. More studies need to examine how clinics with dissimilar resources, different therapeutic Phe targets and frequency of monitoring relate to metabolic control.
id UFMG_aa5aa54bedc2f09af5a2ad0e1325aebb
oai_identifier_str oai:repositorio.ufmg.br:1843/52415
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling 2023-04-24T20:33:38Z2023-04-24T20:33:38Z2021-09-06139https://doi.org/10.3390/nu130931182072-6643http://hdl.handle.net/1843/52415https://orcid.org/0000-0002-1683-1314https://orcid.org/0000-0001-7401-4016https://orcid.org/0000-0002-9247-9391https://orcid.org/0000-0002-8727-3743https://orcid.org/0000-0002-4977-8345Blood phenylalanine (Phe) is used as the primary marker to evaluate metabolic control. Our study aimed to describe the metabolic control of patients with phenylketonuria (PKU) comparing three different treatment recommendations (European guidelines/US guidelines/Portuguese consensus). This was a retrospective, observational, single centre study in patients with PKU collecting data on blood Phe levels from 2017. Nutritional intake data and sapropterin (BH4) prescription were collected at the last appointment of 2017. The final sample studied included 87 patients (48% females) [13 hyperphenylalaninemia; 47 mild PKU; 27 classical PKU] with a median age of 18 y (range: 1–36 y). The median number of blood Phe measurements for patients was 21 (range: 6–89). In patients aged < 12 y, the median blood Phe level was 300 µmol/L (range 168–480) and 474 µmol/L (range 156–1194) for patients ≥ 12 y. Overall, a median of 83% of blood Phe levels were within the European PKU guidelines target range. In patients aged ≥ 12 years, there was a higher median % of blood Phe levels within the European PKU guidelines target range (≥12 y: 84% vs. <12 y: 56%). In children < 12 y with classical PKU (n = 2), only 34% of blood Phe levels were within target range for all 3 guidelines and 49% with mild PKU (n = 11). Girls had better control than boys (89% vs. 66% median Phe levels within European Guidelines). Although it is clear that 50% or more patients were unable to achieve acceptable metabolic control on current treatment options, a globally agreed upper Phe target associated with optimal outcomes for age groups is necessary. More studies need to examine how clinics with dissimilar resources, different therapeutic Phe targets and frequency of monitoring relate to metabolic control.A fenilalanina sanguínea (Phe) é usada como marcador primário para avaliar o controle metabólico. Nosso estudo teve como objetivo descrever o controle metabólico de pacientes com fenilcetonúria (PKU) comparando três diferentes recomendações de tratamento (diretrizes europeias/diretrizes americanas/consenso português). Este foi um estudo retrospectivo, observacional, de centro único em pacientes com PKU coletando dados sobre os níveis de Phe no sangue de 2017. Dados de ingestão nutricional e prescrição de sapropterina (BH4) foram coletados na última consulta de 2017. A amostra final estudada incluiu 87 pacientes (48 % mulheres) [13 hiperfenilalaninemia; 47 PKU leve; 27 clássica PKU] com uma idade média de 18 anos (intervalo: 1-36 anos). O número médio de medições de Phe no sangue para os pacientes foi de 21 (intervalo: 6-89). Em pacientes com idade < 12 anos, o nível médio de Phe no sangue foi de 300 µmol/L (intervalo 168–480) e 474 µmol/L (intervalo 156–1194) para pacientes ≥ 12 anos. No geral, uma média de 83% dos níveis de Phe no sangue estavam dentro da faixa-alvo das diretrizes europeias de PKU. Em pacientes com idade ≥ 12 anos, houve uma porcentagem mediana mais alta de níveis de Phe no sangue dentro da faixa-alvo das diretrizes europeias de PKU (≥12 anos: 84% vs. <12 anos: 56%). Em crianças < 12 anos com PKU clássica (n = 2), apenas 34% dos níveis de Phe no sangue estavam dentro da faixa-alvo para todas as 3 diretrizes e 49% com PKU leve (n = 11). As meninas tiveram melhor controle do que os meninos (89% vs. 66% dos níveis médios de Phe dentro das Diretrizes Europeias). Embora esteja claro que 50% ou mais dos pacientes foram incapazes de alcançar um controle metabólico aceitável nas opções de tratamento atuais, é necessário um alvo de Phe superior globalmente acordado associado a resultados ideais para as faixas etárias. Mais estudos precisam examinar como clínicas com recursos diferentes, diferentes alvos terapêuticos de Phe e frequência de monitoramento se relacionam com o controle metabólico.Outra AgênciaengUniversidade Federal de Minas GeraisUFMGBrasilHCL - HOSPITAL DAS CLINICASNutrientsFenilcetonúriasFenilalaninaAminoácidos - MetabolismoPhenylketonuriaPhenylalanineMetabolic controlGuidelinesMetabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendationsControle metabólico de doentes com fenilcetonúria num centro metabólico português comparando três diferentes recomendaçõesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.mdpi.com/2072-6643/13/9/3118Viviane de Cássia KanufreManuela Ferreira AlmeidaCatarina Sousa BarbosaCarla CarmonaAnabela BandeiraEsmeralda MartinsSara RochaArlindo GuimasRosa RibeiroAnita MacDonaldAlex PintoJúlio César Rochaapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/52415/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALMetabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.pdfMetabolic Control of Patients with Phenylketonuria in a Portuguese Metabolic Centre Comparing Three Different Recommendations.pdfapplication/pdf399237https://repositorio.ufmg.br/bitstream/1843/52415/2/Metabolic%20Control%20of%20Patients%20with%20Phenylketonuria%20in%20a%20Portuguese%20Metabolic%20Centre%20Comparing%20Three%20Different%20Recommendations.pdf532ecdf3a802f0567e0d571336eaaee9MD521843/524152023-04-24 17:33:38.59oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-04-24T20:33:38Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.pt_BR.fl_str_mv Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
dc.title.alternative.pt_BR.fl_str_mv Controle metabólico de doentes com fenilcetonúria num centro metabólico português comparando três diferentes recomendações
title Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
spellingShingle Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
Viviane de Cássia Kanufre
Phenylketonuria
Phenylalanine
Metabolic control
Guidelines
Fenilcetonúrias
Fenilalanina
Aminoácidos - Metabolismo
title_short Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
title_full Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
title_fullStr Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
title_full_unstemmed Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
title_sort Metabolic control of patients with phenylketonuria in a portuguese metabolic centre comparing three different recommendations
author Viviane de Cássia Kanufre
author_facet Viviane de Cássia Kanufre
Manuela Ferreira Almeida
Catarina Sousa Barbosa
Carla Carmona
Anabela Bandeira
Esmeralda Martins
Sara Rocha
Arlindo Guimas
Rosa Ribeiro
Anita MacDonald
Alex Pinto
Júlio César Rocha
author_role author
author2 Manuela Ferreira Almeida
Catarina Sousa Barbosa
Carla Carmona
Anabela Bandeira
Esmeralda Martins
Sara Rocha
Arlindo Guimas
Rosa Ribeiro
Anita MacDonald
Alex Pinto
Júlio César Rocha
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Viviane de Cássia Kanufre
Manuela Ferreira Almeida
Catarina Sousa Barbosa
Carla Carmona
Anabela Bandeira
Esmeralda Martins
Sara Rocha
Arlindo Guimas
Rosa Ribeiro
Anita MacDonald
Alex Pinto
Júlio César Rocha
dc.subject.por.fl_str_mv Phenylketonuria
Phenylalanine
Metabolic control
Guidelines
topic Phenylketonuria
Phenylalanine
Metabolic control
Guidelines
Fenilcetonúrias
Fenilalanina
Aminoácidos - Metabolismo
dc.subject.other.pt_BR.fl_str_mv Fenilcetonúrias
Fenilalanina
Aminoácidos - Metabolismo
description Blood phenylalanine (Phe) is used as the primary marker to evaluate metabolic control. Our study aimed to describe the metabolic control of patients with phenylketonuria (PKU) comparing three different treatment recommendations (European guidelines/US guidelines/Portuguese consensus). This was a retrospective, observational, single centre study in patients with PKU collecting data on blood Phe levels from 2017. Nutritional intake data and sapropterin (BH4) prescription were collected at the last appointment of 2017. The final sample studied included 87 patients (48% females) [13 hyperphenylalaninemia; 47 mild PKU; 27 classical PKU] with a median age of 18 y (range: 1–36 y). The median number of blood Phe measurements for patients was 21 (range: 6–89). In patients aged < 12 y, the median blood Phe level was 300 µmol/L (range 168–480) and 474 µmol/L (range 156–1194) for patients ≥ 12 y. Overall, a median of 83% of blood Phe levels were within the European PKU guidelines target range. In patients aged ≥ 12 years, there was a higher median % of blood Phe levels within the European PKU guidelines target range (≥12 y: 84% vs. <12 y: 56%). In children < 12 y with classical PKU (n = 2), only 34% of blood Phe levels were within target range for all 3 guidelines and 49% with mild PKU (n = 11). Girls had better control than boys (89% vs. 66% median Phe levels within European Guidelines). Although it is clear that 50% or more patients were unable to achieve acceptable metabolic control on current treatment options, a globally agreed upper Phe target associated with optimal outcomes for age groups is necessary. More studies need to examine how clinics with dissimilar resources, different therapeutic Phe targets and frequency of monitoring relate to metabolic control.
publishDate 2021
dc.date.issued.fl_str_mv 2021-09-06
dc.date.accessioned.fl_str_mv 2023-04-24T20:33:38Z
dc.date.available.fl_str_mv 2023-04-24T20:33:38Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1843/52415
dc.identifier.doi.pt_BR.fl_str_mv https://doi.org/10.3390/nu13093118
dc.identifier.issn.pt_BR.fl_str_mv 2072-6643
dc.identifier.orcid.pt_BR.fl_str_mv https://orcid.org/0000-0002-1683-1314
https://orcid.org/0000-0001-7401-4016
https://orcid.org/0000-0002-9247-9391
https://orcid.org/0000-0002-8727-3743
https://orcid.org/0000-0002-4977-8345
url https://doi.org/10.3390/nu13093118
http://hdl.handle.net/1843/52415
https://orcid.org/0000-0002-1683-1314
https://orcid.org/0000-0001-7401-4016
https://orcid.org/0000-0002-9247-9391
https://orcid.org/0000-0002-8727-3743
https://orcid.org/0000-0002-4977-8345
identifier_str_mv 2072-6643
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Nutrients
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.publisher.initials.fl_str_mv UFMG
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv HCL - HOSPITAL DAS CLINICAS
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
bitstream.url.fl_str_mv https://repositorio.ufmg.br/bitstream/1843/52415/1/License.txt
https://repositorio.ufmg.br/bitstream/1843/52415/2/Metabolic%20Control%20of%20Patients%20with%20Phenylketonuria%20in%20a%20Portuguese%20Metabolic%20Centre%20Comparing%20Three%20Different%20Recommendations.pdf
bitstream.checksum.fl_str_mv fa505098d172de0bc8864fc1287ffe22
532ecdf3a802f0567e0d571336eaaee9
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv
_version_ 1801676609618444288